Top

Published in:

01-08-2009 | Brief Communication

Quality of life and seizure control in patients with brain tumor-related epilepsy treated with levetiracetam monotherapy: preliminary data of an open-label study

Authors: Loredana Dinapoli, Marta Maschio, Bruno Jandolo, Alessandra Fabi, Andrea Pace, Francesca Sperati, Paola Muti

Published in: Neurological Sciences | Issue 4/2009

Abstract

The aim of this pilot study was to investigate the effects of levetiracetam monotherapy on seizure control, quality of life and neurocognitive performance in patients with brain tumor-related epilepsy. We present here preliminary data from 18 patients with follow-up of 6 months. We evaluated seizure frequency at baseline. We used administered Mini Mental State Examination (MMSE), Karnofsky Performance Status (KPS), Barthel index (BI), QOLIE 31P (V2), EORTC QLQ-C30 and Adverse Events Profile. After 6 months, 16 patients were seizure free (88.9%), 2 (11.1%) had reduction in seizure frequency >50%. Compared to baseline, we observed a worsening of performance (KPS p = 0.011; BI = 0.008) and global lower cognitive performance (MMSE p = 0.011); distress related to seizure frequency (p = 0.003) and medication effects (p = 0.046) were significantly lower. Levetiracetam caused mild and reversible side effects. These preliminary data on LEV monotherapy in patients with brain tumor-related epilepsy show that this antiepileptic drug is efficacious and well tolerated.

Edvardsson T, Ahlström G (2005) Illness-related problems and coping among persons with low-grade glioma. Psychooncology 14:728–737PubMedCrossRef

Klein M, Heimans JJ, Aaronson NK et al (2002) Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low grade gliomas: a comparative study. Lancet 360:1361–1368PubMedCrossRef

Mainio A, Hakko H, Timonen M, Niemelä A, Koivukangas J, Räsänen P (2005) Depression in relation to survival among neurosurgical patients with a primary brain tumor: a 5-year follow-up study. Neurosurgery 56:1234–1241PubMedCrossRef

Lynam LM, Lyons MK, Drazkowski JF, Sirven JI, Noe KH, Zimmerman RS, Wilkens JA (2007) Frequency of seizures in patients with newly diagnosed brain tumors: a retrospective review. Clin Neurol Neurosurg 109:634–638PubMedCrossRef

van Breemen MS, Wilms EB, Vecht CJ (2007) Epilepsy in patients with brain tumors: epidemiology, mechanisms, and management. Lancet Neurol 6:421–430PubMedCrossRef

Maschio M, Albani F, Baruzzi A et al (2006) Levetiracetam therapy in patients with brain tumor and epilepsy. J Neurooncol 80:97–100PubMedCrossRef

Klein M, Engelberts NH, van der Ploeg HM et al (2003) Epilepsy in low-grade gliomas: the impact on cognitive function and quality of life. Ann Neurol 54:514–520PubMedCrossRef

Glantz MJ, Cole BF, Forsyth PA et al (2000) Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Neurology 54:1886–1893PubMed

Oberndorfer S, Piribauer M, Marosi C, Lahrmann H, Hitzenberger P, Grisold W (2005) P450 enzyme inducing and non-enzyme inducing antiepileptics in glioblastoma patients treated with standard chemotherapy. J Neurooncol 72:255–260PubMedCrossRef

10.

Contin M, Albani F, Riva R, Baruzzi A (2004) Levetiracetam therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs. Ther Drug Monit 26:375–379PubMedCrossRef

11.

Maschio M, Dinapoli L, Zarabla A, Jandolo B (2006) Issues related to the pharmacological management of patients with brain tumors and epilepsy. Funct Neurol 21:15–19PubMed

12.

Newton HB, Goldlust SA, Pearl D (2006) Retrospective analysis of the efficacy and tolerability of levetiracetam in brain tumor patients. J Neurooncol 78:99–102PubMedCrossRef

13.

Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events v3.0, DCTD, NCI, NIH, DHHS. http://ctep.cancer.gov. Accessed 12 December 2003

14.

Apolone G, Filiberti A, Cifani S, Ruggiata R, Mosconi P (1998) Evaluation of the EORTC QLQ-C30 questionnaire: a comparison with SF-36 Health Survey in a cohort of Italian long-survival cancer patients. Ann Oncol 9:549–557PubMedCrossRef

15.

Cramer JA, Van Hammée G, N132 Study Group (2003) Maintenance of improvement in health-related quality of life during long-term treatment with levetiracetam. Epilepsy Behav 4:118–123PubMedCrossRef

16.

Gilliam FG, Fessler AJ, Baker G, Vahle V, Carter J, Attarian H (2004) Systematic screening allows reduction of adverse antiepileptic drug effects: a randomized trial. Neurology 62:23–27PubMed

17.

Brown PD, Buckner JC, O’Fallon JR et al (2003) Effects of radiotherapy on cognitive function in patients with low-grade glioma measured by the folstein mini-mental state examination. J Clin Oncol 21:2519–2524PubMedCrossRef

18.

Karnofsky DA, Burchenal JH, Armistead GC, Southam CM, Bernstein JL, Craver LF, Rhoads CP (1951) Triethylene melamine in the treatment of neoplastic disease. Arch Int Med 87:477–516

19.

Mahoney FI, Barthel DW (1965) Functional evaluation: the Barthel Index. Md State Med J 14:61–65PubMed

20.

Beaumont A, Whittle IR (2000) The pathogenesis of tumor associated epilepsy. Acta Neurochir 142:1–15CrossRef

21.

Baltes S, Gastens AM, Fedrowitz M, Potschka H, Kaever V, Löscher W (2007) Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology 52:333–346PubMedCrossRef

22.

Brada M, Viviers L, Abson C et al (2003) Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. Ann Oncol 14:1715–1721PubMedCrossRef

23.

Perucca E, Meador KJ (2005) Adverse effects of antiepileptic drugs. Acta Neurol Scand Suppl 181:30–35PubMedCrossRef

24.

Meyers CA, Hess KR (2003) Multifaceted end points in brain tumor clinical trials: cognitive deterioration precedes MRI progression. Neuro Oncol 5:89–95PubMedCrossRef

Title: Quality of life and seizure control in patients with brain tumor-related epilepsy treated with levetiracetam monotherapy: preliminary data of an open-label study
Authors: Loredana Dinapoli
Marta Maschio
Bruno Jandolo
Alessandra Fabi
Andrea Pace
Francesca Sperati
Paola Muti
Publication date: 01-08-2009
Publisher: Springer Milan
Published in: Neurological Sciences / Issue 4/2009
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-009-0087-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Quality of life and seizure control in patients with brain tumor-related epilepsy treated with levetiracetam monotherapy: preliminary data of an open-label study

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2009

Can demographic and admission laboratory variables be useful to identify long-stay patients with acute ischemic stroke? A hospital-based cohort study in Singapore

Medulla oblongata tuberculoma mimicking metastasis presenting with stroke-like symptoms

Determination of nerve conduction abnormalities in patients with impaired glucose tolerance

Interesting sign of Bell’s palsy in an ear wiggler

Predictable variables for short- and long-term botulinum toxin treatment response in patients with cervical dystonia

Primary gait ignition disorder: report of three cases